OnCARlytics(Imugene)

N/A

Report date: 2026/03/07 20:00:27

Base Information

Drug NameOnCARlytics(Imugene)
Drug Alias NameCF-33-CD-19
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsT lymphocyte replacementsImmunologic cytotoxicity +[4] 
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical CenterImugene Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImugene Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A